Patients with idiopathic pulmonary fibrosis (IPF) are at a high risk of lung cancer (LC). Antifibrotic therapy slows disease progression and possibly prolongs survival. However, whether antifibrotic therapy affects LC development in patients with IPF remains unknown. This multicentre retrospective study evaluated 345 patients with IPF. The incidence and prevalence of LC were significantly lower in patients with IPF receiving antifibrotic therapy than those not receiving. Subsequently, LC-related mortality was significantly lower in patients with IPF receiving antifibrotic therapy. These results suggest that antifibrotic therapy was possibly associated with a reduced risk of LC development in patients with IPF, which may be partly associated with its survival benefit.

中文翻译：

---

抗纤维化治疗对特发性肺纤维化肺癌发展的影响

特发性肺纤维化 (IPF) 患者患肺癌 (LC) 的风险很高。抗纤维化治疗可减缓疾病进展并可能延长生存期。然而，抗纤维化治疗是否会影响 IPF 患者的 LC 发展仍然未知。这项多中心回顾性研究评估了 345 名 IPF 患者。接受抗纤维化治疗的 IPF 患者的 LC 发生率和患病率明显低于未接受抗纤维化治疗的患者。随后，接受抗纤维化治疗的 IPF 患者的 LC 相关死亡率显着降低。这些结果表明，抗纤维化治疗可能与 IPF 患者发生 LC 的风险降低有关，这可能部分与其生存获益有关。